生物标志物在评价急性肺栓塞严重程度及预后中的研究进展

Research progress of biomarkers in evaluating the severity and prognosis of acute pulmonary embolism

肺栓塞是指来源于机体的各种栓子将肺动脉或其分支阻塞,从而引起一系列临床综合征的疾病,是全球第三大常见的心血管病死因。由于急性肺栓塞缺乏典型的临床表现,且需要通过特定的检查方法,因此该病漏诊率高。急性肺栓塞的临床管理具有复杂性和困难性。因此,快速地做出诊断并给予合适的治疗方案决定了急性肺栓塞的预后。国内外研究显示,生物标志物在临床上应用较为广泛,其使用价值更是不可估量的。本文对生物标志物在急性肺栓塞的病情严重程度判断及预后评估进行简要综述。

Pulmonary embolism is a disease in which various emboli from the body block the pulmonary artery or its branches,causing a series of clinical syndromes.It is the third most common cause of cardiovascular death in the world.Acute pulmonary embolism lacks typical clinical manifestations and requires specific examination methods,so the missed diagnosis rate of the disease is high.And the clinical management of acute pulmonary embolism is complicated and difficult.Therefore,the rapid diagnosis and appropriate treatment plan determine the prognosis of acute pulmonary embolism.Numerous studies have shown that biomarkers are widely used in clinical practice,and their value is immeasurable.This article briefly reviews the biomarkers in the evaluation of severity and prognosis of acute pulmonary embolism.